Citigroup's report states that due to strong sales growth of biosimilars and innovative drugs, China Medical System (01177.HK) expected to have a strong performance in the first half of the year, with profits expected to increase by about 10% year-on-year. With an increase in sales of biosimilars, G-CSF and Cataplasms, the company's performance in the second half of the year is expected to have higher visibility.

The bank has initiated a 30-day upward catalytic observation on China Medical System. The target price is 6.8 yuan and the rating is "buy".